Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Company profile updated November 7, 2026.
As of November 6, 2026. Daily closing data may differ from the live quote shown in the dashboard.
Compare the company’s price history and fundamentals in the dashboard. Explore disclosed trading and ownership activity in these research collections: